Other Viruses Citation List: May 25 - June 7, 2012
Hepatitis C Virus
1. Finger Loop Inhibitors of the HCV NS5b Polymerase. Part II. Optimization of Tetracyclic Indole-based Macrocycle Leading to the Discovery of TMC647055. Vendeville, S., T.I. Lin, L. Hu, A. Tahri, D. McGowan, M.D. Cummings, K. Amssoms, M. Canard, S. Last, I. Van den Steen, B. Devogelaere, M.C. Rouan, L. Vijgen, J.M. Berke, P. Dehertogh, E. Fransen, E. Cleiren, L. van der Helm, G. Fanning, K. Van Emelen, O. Nyanguile, K. Simmen, and P. Raboisson, Bioorganic & Medicinal Chemistry Letters, 2012. [Epub ahead of print]; PMID[22633687].
[PubMed]. OV_0525-060712.
2. First-in-human Pharmacokinetics and Antiviral Activity of IDX375, a Novel Non-nucleoside Hepatitis C Virus Polymerase Inhibitor. de Bruijne, J., V.D.W.d.R. J, A.A. van Vliet, X.J. Zhou, M.F. Temam, J. Molles, J. Chen, K. Pietropaolo, J.Z. Sullivan-Bolyai, D. Mayers, and H.W. Reesink, Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[22664976].
[PubMed]. OV_0525-060712.
3. Tri-substituted Acylhydrazines as Tertiary Amide Bioisosteres: HCV NS5B Polymerase Inhibitors. Canales, E., J.S. Carlson, T. Appleby, M. Fenaux, J. Lee, Y. Tian, N. Tirunagari, M. Wong, and W.J. Watkins, Bioorganic & Medicinal Chemistry Letters, 2012. [Epub ahead of print]; PMID[22664130].
[PubMed]. OV_0525-060712.
HSV-1
4. Cascade Search for HSV-1 Combinatorial Drugs with High Antiviral Efficacy and Low Toxicity. Ding, X., D.J. Sanchez, A. Shahangian, I. Al-Shyoukh, G. Cheng, and C.M. Ho, International Journal of Nanomedicine, 2012. 7: p. 2281-2292; PMID[22654513].
[PubMed]. OV_0525-060712.
5. Anti-herpes Virus Activities of Bioactive Fraction and Isolated Pure Constituent of Mallotus peltatus: An Ethnomedicine from Andaman Islands. Bag, P., D. Chattopadhyay, H. Mukherjee, D. Ojha, N. Mandal, M.C. Sarkar, T. Chatterjee, G. Das, and S. Chakraborti, Virology Journal, 2012. 9(1): p. 98; PMID[22624581].
[PubMed]. OV_0525-060712.
Citations from the ISI Web of Knowledge Listings for O.V.
6. Synthesis and Biological Evaluation of (3 ' S)-3 '-Deoxy-3 '-fluoro-3 '-C-ethynlcytidine. Clark, J.L., C.B. Clark, and J.C. Mason, Nucleosides Nucleotides & Nucleic Acids, 2012. 31(4): p. 286-292; ISI[000303579100002].
[WOS]. OV_0525-060712.
7. In Vitro Characterization of the Anti-viral Activity of TT-034, a RNAi-Therapeutic against the Hepatitis C Virus. Lavender, H., K. Brady, F. Burden, O. Delpuech-Adams, H. Denise, A. Palmer, H. Perkins, B. Savic, S. Scott, C. Smith-Burchnell, S. Moschos, P. Troke, F. Wright, R. Corbau, and D. Suhy, Molecular Therapy, 2012. 20: p. S256-S256; ISI[000303484600660].
[WOS]. OV_0525-060712.
8. HCV Inhibition by a Multicistronic anti-HCV miRNA AAV Vector in Vitro and in Vivo. Marcucci, K.T., X. Yang, S.Z. Zhou, G.X. Luo, and L.B. Couto, Molecular Therapy, 2012. 20: p. S128-S129; ISI[000303484600327].
[WOS]. OV_0525-060712.
9. An Engineered Inhibitor RNA that Efficiently Interferes with Hepatitis C Virus Translation and Replication. Romero-Lopez, C., B. Berzal-Herranz, J. Gomez, and A. Berzal-Herranz, Antiviral Research, 2012. 94(2): p. 131-138; ISI[000303692000003].
[WOS]. OV_0525-060712.
10. A QSAR Study on Some Thiophene Derivatives Acting as anti-HCV Agents. Varshney, J., A. Sharma, and S.P. Gupta, Letters in Drug Design & Discovery, 2012. 9(4): p. 389-396; ISI[000303681400006].
[WOS]. OV_0525-060712.